KRAS and metabolic dysfunction-associated steatotic liver disease: For example, combining MIF inhibitors (e.g., IPG1576) with immunotherapies or KRAS-targeted therapies might offer synergy, particularly in patients with concurrent MASLD where the hepatic microenvironment is critical.